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We are pleased to present this report, Pharmacare 2020, 
which is the culmination of many years of research and 
collaboration involving academics, health professionals, 
policy-makers, and public interest groups.
Pharmacare 2020 was a collaborative initiative of the 
Pharmaceutical Policy Research Collaboration, a CIHR/Health 
Canada Emerging Team on Equity in Access to Necessary 
Medicines (2009–2014). Its goal was to foster evidence-
informed conversation on the future of prescription drug 
coverage in Canada.
The name, Pharmacare 2020, was chosen because it alluded to 
two important issues.
First, we were motivated to address the lack of a clear vision 
in policy discussions concerning what Pharmacare is — or what 
it ought to be. Although the term Pharmacare has been used 
in Canada since the 1960s, many people have rightfully asked 
what it means.
We therefore sought to provide a clear vision of Pharmacare 
by identifying the principles and features of a system of drug 
coverage in Canada that would best achieve the key goals of 
prescription drug financing policy. 
We arrived at the final vision through a combination of 
dialogue — with researchers, policy-makers, patients, health 
charities, health professionals, and industry stakeholders — and 
rigorous pharmaceutical policy research, much of which we 
have published in top journals and with leading think-tanks.
In the end, theory, evidence, and policy experience all pointed 
toward a clear and coherent vision of a system of prescription 
drug benefits that would best address the following four key 
policy goals for Canadians:
• Access: universal access to necessary medicines
• Fairness: fair distribution of prescription drug costs 
• Safety: safe and appropriate prescribing
• Value for money: maximum health benefits per dollar spent. 
The vision is of a public drug plan that follows four policy 
recommendations:
1. Provide universal coverage of selected medicines at little or 
no direct cost to patients through Pharmacare.
2. Select and finance medically necessary prescription drugs 
at a population level without needs-based charges — such 
as deductibles, coinsurance, or risk-rated premiums — on 
individuals or other plan sponsors (e.g., businesses).  
3. Establish a publicly accountable body to manage 
Pharmacare, one that integrates the best available data 
and evidence into decisions concerning drug coverage, drug 
prescribing, and patient follow-up.
4. Establish Pharmacare as a single-payer system with a 
publicly accountable management agency to secure the best 
health outcomes for Canadians from a transparent drug budget. 
This is Pharmacare for Canada. It would work in conjunction 
with Canadian Medicare to promote the health and well-being 
of Canadians.
This vision of what Pharmacare is — or should be — for Canada 
is shared not only by the authors of this final report. The 
recommendations of this report have been reviewed and 
endorsed by over 100 university-affiliated professors and 
clinical experts in pharmaceutical policy, health policy, health 
economics, health services research, medicine, pharmacy, 
nursing, and psychology. Furthermore, the public opinion 
research by the Angus Reid Institute that is cited in this report 
suggests that a vast majority of Canadians share this vision too.
The second important issue that the name Pharmacare 
2020 alludes to is a timeline. Canada has been waiting for 
Pharmacare since the 1960s. The vision is now clear. Thus, the 
task turns to the art and science of program development and 
implementation. This will be difficult and will require political 
leadership and inter-jurisdictional collaboration — but it is not 
impossible, as Canadian Medicare has shown. This led to our 
fifth policy recommendation:
5. Fully implement Pharmacare — a public drug plan 
that is universal, comprehensive, evidence-based, and 
sustainable — by 2020. 
We chose 2020 because it defines a reasonable timeline for 
reform — short enough to ensure that action is taken soon, 
but long enough to ensure that implementation is done 
right. We hope the readers of this report will agree and will 
work collaboratively toward implementation of Pharmacare 
by 2020.
Respectfully,
Steven G. Morgan, PhD, University of British Columbia
Danielle Martin, MD, CCFP, MPP, University of Toronto
Marc-André Gagnon, PhD, Carleton University
Barbara Mintzes, PhD, University of Sydney
Jamie R. Daw, MSc, Harvard University
Joel Lexchin, MD, MSc, York University
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Summary
The World Health Organization has declared that all nations are 
obligated to ensure equitable access to necessary medicines 
through pharmaceutical policies that work in conjunction with 
broader systems of universal health coverage. To that end, every 
developed country with a universal health care system provides 
universal coverage of prescription drugs — except Canada.
All Canadians deserve equitable access to necessary medicines. 
Universal “Pharmacare” — working in conjunction with our 
“Medicare” system — is the best way to achieve this at a fair and 
affordable cost to patients and society as a whole.
Canada’s federal, provincial, and territorial governments 
should commit to a plan that will see full implementation 
of a public drug plan that is universal, comprehensive, 
evidence-based, and sustainable. This is Pharmacare for 
Canada.
Pharmacare is a natural, long-planned component of 
Canadian Medicare. Full implementation by 2020 is 
both desirable and feasible. Such a timeline signals 
firm commitment while allowing time for careful 
implementation of this important, long-term program.
Evidence from across Canada and around the world shows 
that Pharmacare is the best system for achieving: 
• universal access to necessary medicines
• fair distribution of prescription drug costs 
• safe and appropriate prescribing, and
• maximum health benefits per dollar spent. 
This report explains why this is the case and therefore 
why Canadians deserve Pharmacare by 2020. 
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There have been calls to include prescription drugs in 
Canada’s universal public health care system since the 
1960s.
In 1964, the Royal Commission on Health Services– known 
as the Hall Commission after its chair, Saskatchewan 
Supreme Court Justice Emmett Hall — recommended 
that Canada implement a universal, public pharmacare 
program following the introduction of universal coverage 
of medical care.
Justice Hall argued that “in view of the high cost of many 
of the new life-saving, life-sustaining, pain-killing, and 
disease-preventing medicines, prescribed drugs should 
be introduced as a benefit of the public health services 
program.” The Hall Commission recommended that 
federal and provincial governments work together to 
make a list of medicines — selected on the basis of their 
clinical and economic value to society — available to all 
Canadians at a cost of just $1 per prescription (about $8 
in today’s terms).
In 1997, the National Forum on Health — an expert 
advisory panel chaired by then Prime Minister Jean 
Chrétien — also recommended that Canada implement a 
universal public drug benefit program. The National Forum 
argued that “because pharmaceuticals are medically 
necessary and public financing is the only reasonable 
way to promote universal access and to control costs, we 
believe Canada should take the necessary steps to include 
drugs as part of its publicly funded health care system.” 
The National Forum recommended that universal public 
drug plans in all provinces make available prescription 
drugs selected on the basis of evidence of clinical and 
economic value. It recommended that the program impose 
user charges only on products that are not the most cost-
effective treatment options — such as when expensive 
brands are used instead of equally effective and lower-
cost generic drugs. 
In 2002, the Commission on the Future of Health 
Care in Canada — named the Romanow Commission 
after its chair, former premier of Saskatchewan, Roy 
Romanow — recommended that all governments in 
Canada work together to integrate medically necessary 
prescription drugs within Canadian medicare. The 
Romanow Commission argued that establishing universal 
“catastrophic” drug coverage — which has effectively been 
done across Canada — was the first step toward “. . . the 
ultimate objective of bringing prescription drugs under the 
Canada Health Act.” 
Mr. Romanow also argued that investments needed 
to be made to ensure that “. . . prescription drugs are 
integrated into the system in a way that ensures they 
are appropriately prescribed and utilized.” To that end, 
he recommended that a national agency be created to 
negotiate drug prices and coverage decisions for the 
universal drug plan, monitor prescribing and drug safety, 
and provide objective information about medicines to 
patients and health care providers.
Despite these calls Canada has made little progress toward 
Pharmacare. Public health insurance programs have 
financed nearly all expenditures on medical care (99% 
public) and hospital care (90% public) in Canada since the 
1970s. In contrast, public drug benefit programs in Canada 
evolved in ways that historically resulted in relatively 
comprehensive public coverage for selected populations, 
such as senior citizens and social assistance recipients. 
Rather than extend such coverage to all Canadians, several 
provinces have moved toward universal drug plans that 
provide all residents protection against “catastrophic” drug 
costs only, regardless of age. 
Though some of the changes in provincial drug plans 
represent a step toward greater universality in coverage, 
they also reflect a retrenchment of public drug benefits 
in Canada. As a share of prescription drug expenditures 
in Canada, government-financed drug plans have shrunk 
from a peak of 47% in 1991 to just 38% today.
Today, growing numbers of individuals, interest groups, 
and even politicians are calling once again for expansion 
of public drug coverage in Canada. The vast majority of 
these groups are calling for “Pharmacare,” the subject of 
this report. 
History of Pharmacare in Canada
Pharmacare is the unfinished business of 
Canadian Medicare
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Pharmacare is the Unfinished Business of Canadian Medicare
Overarching principle: All 
Canadians deserve equitable 
access to safe, cost-effective, 
and appropriately prescribed 
medicines at a fair and 
affordable cost to patients and 
society as a whole.
Prescription drugs are among the most important 
components of modern health care. When prescribed and 
used appropriately, they can prevent and cure disease, 
and extend and improve the quality of life.
Pharmaceuticals are so essential to health and well-
being that the World Health Organization has declared 
that all nations should ensure universal access to 
necessary medicines.1 The World Health Organization 
also recommends that this be accomplished through 
pharmaceutical policies that work in conjunction with 
broader systems of universal health coverage.2
Consistent with these recommendations, every developed 
country with a universal health care system provides 
universal coverage of medically necessary prescriptions. 
Every such country except Canada, that is.
Canada has a universal, comprehensive public health 
insurance system for medical and hospital care — our 
“Medicare” system. Conspicuously, however, coverage of 
prescription drugs used outside hospitals in Canada is 
neither universal nor comprehensive. 
1 The Selection of Essential Medicines. World Health Organization. 2002. 
http://apps.who.int/medicinedocs/en/d/Js2296e/1.html 
2 See discussion in Medicines in Health Systems: Advancing Access, 
Affordability and Appropriate Use. World Health Organization. 2014.  
http://www.who.int/alliance-hpsr/resources/FR_webfinal_v1.pdf
3 The Canadian Rx Atlas, 3rd Edition. University of British Columbia. 2013. 
https://circle.ubc.ca/handle/2429/50349 
4 National Health Expenditure Trends, 1975 to 2014. Canadian Institute for 
Health Information. 2014. http://www.cihi.ca/CIHI-ext-portal/pdf/internet/
nhex_2014_report_en
Drug coverage in Canada 
can best be described 
as an incomplete and 
uncoordinated patchwork 
of public and private drug 
plans. This patchwork 
leaves many patients with 
little or no coverage at all 
and, because it fragments 
our purchasing power, 
results in higher drug costs 
for all Canadians.
Canadians will fill over 
500 million prescriptions 
at retail pharmacies this 
year.3 This will cost about 
$30 billion.4 Although this 
amount is less than the 
$64 billion spent on all 
forms of hospital care, it is 
nearly as much as the $33 
billion paid for all medical 
and diagnostic services 
provided by physicians in 
Canada, and it is more than 
double the $13 billion cost 
of all dental care. 
Thirty billion dollars is 
also four times as much as 
we spent on prescriptions 
20 years ago. No other 
component of Canadian 
health care has grown as 
quickly.
Every developed 
country with a 




drugs — except 
Canada
Introduction
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Although pharmaceuticals used in Canadian hospitals are 
fully covered under our Medicare system, most Canadians 
receive no public assistance with the costs of prescriptions 
they fill at pharmacies.
Public drug plans vary across Canada, with some covering 
patients based on age, some based on income, and some 
based on specific medical needs (such as cancer, HIV, or 
cystic fibrosis). In total, public drug plans cover $12 billion 
in prescriptions, or 42% of all prescription drug costs in 
Canada.5  
Private drug plans cover 36% of prescription drug costs in 
Canada. These plans are voluntary in all provinces except 
Quebec, where employers are required to provide private 
drug insurance for eligible employees. Most private 
insurance is obtained through work-related extended 
health benefits, which are typically available only to full-
time employees working for large organizations.6  
Many Canadians do not have any drug insurance, 
and those who are insured must pay insurance plan 
deductibles and co-payments out-of-pocket. As a 
consequence, Canadian patients pay out-of-pocket for $6 
billion in prescriptions, or 22% of all prescription drug 
costs in Canada.
In addition to being incomplete, our patchwork of drug 
plans in Canada is uncoordinated. Canada’s private and 
public drug plans are not consistent within provinces or 
across the country. They are also not well coordinated 
with broader health care policies in Canada. Private 
drug plans, in particular, are designed not in accordance 
with good health care policy but as part of complex 
labour negotiations that focus on the cost and perceived 
generosity of compensation packages.7
Coverage of medicines in Canada therefore depends 
on a patient’s age, income, workplace, and province of 
residence, but not necessarily on her or his medical needs. 
5 Drug Spending in 2014. Canadian Institute for Health Information. 2014. 
http://www.cihi.ca/web/resource/en/nhex_2014_infosheet_en.pdf 
6 Workplace and Employee Survey Compendium. Statistics Canada. 2008. 
http://www.statcan.gc.ca/pub/71-585-x/71-585-x2008001-eng.pdf. Low 
Earnings, Unfilled Prescriptions: Employer-Provided Health Benefit Coverage 
in Canada. Wellesley Institute. 2015. http://www.wellesleyinstitute.com/
7 “Reforming private drug coverage in Canada: Inefficient drug benefit 
design and the barriers to change in unionized settings.” Health Policy. 
2015. http://www.ncbi.nlm.nih.gov/pubmed/25498311
8 Prescription drug access and affordability an issue for nearly a quarter of 
all Canadian households. Angus Reid Institute. 2015 http://angusreid.org/ 
This creates inequities and inconsistencies in care and 
places undue strain on Canadian citizens and businesses.
It doesn’t have to be that way.
The notion of Pharmacare for Canada has been 
identified by royal commissions dating as far back 
as the 1960s (see story / Page 3). The evidence for 
their recommendations — for drug coverage that is 
universal, comprehensive, publicly managed, and 
evidence-based — remains as solid today as it has ever 
been.
Indeed, based on core values and sound evidence, 
vast and growing numbers of citizens, public interest 
groups, health professionals, health charities, 
businesses, labour groups, municipalities, news media, 
health system managers, and health policy experts 
are calling once again for an improved system of 
prescription drug coverage in Canada. Like the royal 
commissions, the vast majority of these groups 
advocate for a system that works in conjunction with 
Canadian Medicare.
In short, Canadians are calling for Pharmacare in Canada. 
Indeed, a July 2015 poll by the Angus Reid Institute found 
that 91% of Canadians support the concept of having 
“Pharmacare” to provide universal access to necessary 
medicines; 88% believe that medicines should be part of 
Medicare; 80% believe that a single-payer system would 
be more efficient; and 89% believe Pharmacare should 
be a joint effort involving provinces and the federal 
government.8 
Introduction
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Pharmacare is a natural, long-planned but as yet 
undelivered component of Canadian Medicare. It would 
make Medicare better. And, while doing so, it would 
lower costs, as demonstrated by the significantly lower 
cost of pharmaceuticals in all comparable countries with 
universal, comprehensive public coverage of necessary 
medicines (see Figure 1). 
Based on extensive research and consultations, this report 
provides a clear vision of what Pharmacare is — or should 
be — for Canada: a public drug plan that is universal, 
comprehensive, evidence-based, and sustainable. 
The four sections that follow explain why Pharmacare is 
the best option for Canada to achieve the four core goals 
of prescription drug financing policy:
• Access: universal access to necessary medicines
• Fairness: fair distribution of prescription drug costs 
• Safety: safe and appropriate prescribing, and
• Value for money: maximum health benefits per dollar 
spent. 
The concluding section outlines the case for Canada’s 
federal, provincial, and territorial governments to 
act now — together — to see full implementation of 
Pharmacare by 2020.
Figure 1: Canada would save billions of dollars 
if we spent the same on pharmaceuticals as 











$-billions Canada would save 
Introduction
 
Overarching recommendation: Canada should 
implement a public drug plan that is universal, 
comprehensive, evidence-based, and sustainable. 
This is Pharmacare for Canada. It is a system 
that should work in conjunction with Canadian 
Medicare to promote the health and well-being 
of Canadians.
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Universal, Comprehensive Coverage to Ensure Access
Principle: All Canadians should 
have equitable access to medically 
necessary prescription drugs.
Ensuring that all Canadians have access to the medicines 
they need is the central goal of drug coverage policy. 
Unfortunately, despite our universal system for covering 
the costs of medical and hospital care, many Canadians 
cannot afford needed medicines.
Surveys have shown that 1 in 10 Canadians do not take 
their medicines as prescribed because of costs.9  This 
affects nearly 1 in 4 Canadian households.10 
In some cases, Canadians cannot afford their prescriptions 
because they have no drug coverage. But even patients 
with insurance can experience financial barriers when 
they must pay deductibles and co-payments.
Research has shown that user-charges of as little as $2 
per prescription can prevent low-income patients from 
filling needed prescriptions, and that even higher-income 
patients may choose not to fill prescriptions when faced 
with modest charges. 11  
Research also shows that income-based drug plans — which 
only cover costs above income-based deductibles — fail to 
promote access to needed medicines.12 This is because the 
deductibles under such programs make patients pay out-
of-pocket for routine but perhaps essential drug therapies.
When patients face financial barriers to necessary 
prescription drugs, it costs all Canadians. 
9 “The effect of cost on adherence to prescription medications in Canada.” 
Canadian Medical Association Journal. 2012. http://www.cmaj.ca/
content/184/3/297. “Cost-related prescription nonadherence in the United 
States and Canada.” Clinical Therapeutics. 2009. http://www.ncbi.nlm.nih.
gov/pubmed/19243719 
10 Prescription drug access and affordability an issue for nearly a quarter of 
all Canadian households. Angus Reid Institute. 2015 http://angusreid.org/
Because patients often do 
not directly and immediately 
feel the benefits of 
preventive therapies — such 
as medicines to reduce 
the risk of heart attacks 
and strokes — they often 
choose to stop taking these 
medicines when faced with 
associated costs. This results 
in predictable increases in 
the use of other health care 
services, which are often 
more expensive than the 
medicines would have cost 
in the first place. Indeed, 
preventable underuse of 
medicines in Canada has 
been estimated to cost the 
country between $1 billion 
and $9 billion annually.13
Effective prescription drug 
coverage policy is therefore 
not about just making sure 
everyone has some form 
of insurance coverage. It is 
about ensuring that every 
Canadian has effective drug 
coverage — coverage that 
provides equitable access 
to necessary care without 
financial barriers. 
1 in 10 Canadians 
do not take 
their medicines 
as prescribed 
because of costs. 
This affects nearly 
1 in 4 Canadian 
households.
9 in 10 Canadians 
believe it is simply 
not right that some 
Canadians have to 
struggle to pay for 
medicine they need.
11 “Prescription drug cost sharing: Associations with medication and 
medical utilization and spending and health.” Journal of the American 
Medical Association. 2007. http://jama.jamanetwork.com/article.
aspx?articleid=207805 
12 Are Income-Based Public Drug Benefit Programs Fit for an Aging 
Population? Institute for Research on Public Policy. 2014. http://irpp.org/
research-studies/study-no50/
13 Clinical Service Proposal: Medication Adherence Services. British Columbia 
Pharmacy Association. 2013. http://www.bcpharmacy.ca/uploads/
Medication_Adherence.pdf
Access
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Equitable access to medically necessary prescription drugs 
does not require that every drug be covered for every 
use. It requires that all patients have access, without 
barriers, to medicines selected with due regard to public 
health relevance, evidence on efficacy and safety, and 
comparative cost-effectiveness. This is not achieved 
through drug programs for select populations or the 
protection of all people against only “catastrophic” costs.
Pharmacare would provide universal and comprehensive 
coverage of medicines chosen based on the best evidence 
of their value in treating the health needs of Canadians. 
Pharmacare would limit or eliminate any direct charges to 
patients for covered medicines, particularly for vulnerable 
populations and persons managing chronic disease, 
thereby eliminating known barriers to access.
Designed in this way, Pharmacare would ensure equitable 
access to covered medicines regardless of patient age, 
income, or occupation. This would increase adherence 
to therapy, improve patient health, and reduce costs 
elsewhere in the health care system.14 
Pharmacare by 2020 would mean that more than 2 
million Canadians will fill prescriptions that they would 
not otherwise be able to afford.15 Among those who would 
have better access to needed care are over 500,000 older 
Canadians who, despite having some public drug coverage, 
face much higher prescription costs than older people in 
comparable countries. 
14 “Prescription drug insurance coverage and patient health outcomes:  
A systematic review.” American Journal of Public Health. 2015.  
http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2014.302240. 
“Full coverage for preventive medications after myocardial infarction.”  
New England Journal of Medicine. 2011. http://www.nejm.org/doi/
full/10.1056/NEJMsa1107913
15 Authors’ analysis based on the Commonwealth Fund 2007 and 2014 
International Health Policy Surveys: http://www.commonwealthfund.org/
publications/surveys
Pharmacare by 2020 would mean that 
more than 2 million Canadians will fill 
prescriptions that they would not otherwise 
be able to afford.
Access
Recommendation: Provide universal coverage of 
medically necessary prescription drugs at little 
or no direct cost to patients through Pharmacare.
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Fairly Distributing the Cost of Needed Care Across the Population 
Principle: No individual or group 
should be financially disadvantaged 
by their health needs.
Once the medicines that all Canadians should have access 
to are identified — with due regard to cost-effectiveness 
and public health priorities — society will need to 
determine how best to pay for them. 
The goal of ensuring equitable access requires that direct 
charges not be a barrier to using needed medicines. The 
core values of Canadian Medicare — as well as a vast body 
of health system literature — suggest that the costs of 
necessary care should not put patients or families at a 
financial disadvantage. Currently, Canada does poorly in 
this regard.
The use of prescription drugs in Canada can impose 
a considerable financial burden on patients. One in 
five Canadian households spends $500 or more on 
prescriptions, and almost one in 10 (8%) spends $1,000 
or more for their prescriptions.16  This occurs because 
many patients are uninsured for medicines, and many 
who are insured still face various direct charges, such as 
deductibles, co-insurance, or prescription co-payments.
These direct costs can add up to considerable sums, 
even for relatively common treatments, because 
medicines are often needed daily for many years. 
Therefore, people with chronic illnesses need assistance 
with predictable, ongoing drug costs — not just insurance 
against unexpected costs.
“Catastrophic” drug coverage will not do. If patients fill 
their prescriptions as needed, the deductibles under 
catastrophic public drug plans are tantamount to a tax on 
16 Rethinking Pharmacare in Canada. C.D. Howe Institute. 2013. https://
www.cdhowe.org/rethinking-pharmacare-in-canada/22009; and 
Prescription drug access and affordability an issue for nearly a quarter of all 
Canadian households. Angus Reid Institute. 2015 http://angusreid.org/
the sick, including elderly Canadians, virtually all of whom 
have predictable needs for prescription drugs.17  
All needs-based means of paying for prescription drug 
costs — including deductibles, co-payments, and risk-rated 
premiums — are borne disproportionately by those with 
significant and/or ongoing health needs. This limits the 
financial protection provided to patients and families. 
Protecting individuals from the cost of necessary 
prescription drugs requires that the costs be shared fairly 
across the entire population.
Consideration should also be given to the burden placed 
on Canadian businesses that sponsor a significant share 
of drug costs through private, work-related drug plans. 
In Quebec, such plans are legally required for all eligible 
employees.
Employment-related drug plans place a burden on 
employers and create inefficiencies in our workforce. This 
is becoming a greater problem as the number and cost of 
specialized medicines increases in Canada.
Specialized medicines are those used to treat serious 
medical conditions, often at considerable cost. A growing 
number of speciality drugs — which can cost $50,000 or 
even $500,000 per patient per year — are now available 
in Canada. Whereas these types of drugs accounted for 
negligible expenses a decade ago, they now account for 
more than 25% of private drug spending in Canada.18 
These costs place considerable financial burdens on 
employers because they can quickly render a company’s 
drug plan unaffordable. Small businesses are especially at 
risk. With private drug coverage decisions made as part 
of labour contract negotiations, employers and unions are 
put in the impossible position of deciding who gets access 
to what treatments. They shouldn’t have to make these 
decisions. 
17 Are Income-Based Public Drug Benefit Programs Fit for an Aging 
Population? Institute for Research on Public Policy. 2014. http://irpp.org/
research-studies/study-no50/
18 “Businesses warned: High-cost prescription drugs put employees’ 
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Similarly, Canadians shouldn’t have to make decisions 
about where to work and when to retire based on 
availability of drug coverage rather than on life and 
career ambitions. This hurts workers, employers, and 
our economy.
As a universal, comprehensive public plan, Pharmacare is 
the most efficient means of providing equitable assistance 
with ongoing medical needs — achieving this goal at far 
less cost than a regulated system of mandatory private 
drug coverage, such as Quebec’s system.19 Pharmacare 
would also create the largest possible risk pool for the 
costs of specialized medicines in Canada, which is the best 
way to protect both patients and employers from the cost 
of rare but expensive medical needs.20
Pharmacare would provide all Canadians with protection 
against the financial burden associated with prescription 
drug needs. Millions of households would no longer have to 
endure ongoing financial strain owing to their health needs.
Pharmacare would also improve the competitiveness 
of Canada’s labour market. Prescription drug benefits 
would no longer be a major consideration in labour 
negotiations or job seeking. An efficiently run system 
would actually bring down the total cost of labour in the 
Canadian economy. 
19 “Quebec should not be the model for national pharmacare.” Globe and 
Mail. 2015. http://www.theglobeandmail.com/globe-debate/quebec-should-
not-be-the-model-for-national-pharmacare/article25135678/ 
20 “Health care in the age of genetic medicine.” Journal of the American 




no longer have to 
endure ongoing 
financial strain owing 
to their health needs.
Fairness
Recommendation 2: Select and finance medically 
necessary prescription drugs at a population level 
without needs-based charges on individuals or 
other plan sponsors (e.g., businesses).
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Smarter Coverage for Safer, More Appropriate Prescribing 
Principle: Prescription drugs 
should only be funded, 
prescribed, and used in 
accordance with the best 
available evidence concerning 
risks and benefits.
The safety of medicines used by Canadians is of 
primary importance. Expanded drug coverage is 
expected to address problems of underuse of needed 
therapies. But coverage may also exacerbate existing 
problems of overuse and misuse of prescription drugs 
in Canada if these drugs are not offered in ways that 
promote safe and appropriate use.
Our fragmented patchwork of private and public 
drug coverage in Canada isolates the management of 
medicines from the management of health care. This 
has particularly negative consequences in terms of 
under-investment in, and divided responsibility for, 
safe and appropriate use of medicines. Although efforts 
have been made to reduce inappropriate prescribing 
and encourage safer use of medicines, we lag behind 
other countries in many respects.
For example, fewer than 1 in 3 doctors in Canada use 
electronic prescribing tools to help identify problems 
with drug doses or interactions. In contrast, about 9 in 
10 doctors use such systems in New Zealand and the 
United Kingdom — countries where public coverage of 
pharmaceuticals and health care are integrated.21  
There is also inadequate monitoring of prescribing 
practices and related health outcomes in Canada. 
21 2012 Commonwealth Fund International Survey of Primary Care Doctors. 
http://www.commonwealthfund.org/publications/surveys/2012/nov/2012-
international-survey
22 Optimal Prescribing and Medication Use in Canada: Challenges and 
Opportunities. Health Council of Canada. 2007. http://healthcouncilcanada.
ca/tree/2.37-HCC_Symposium_Paper_FA.pdf
23 Drug Use Among Seniors on Public Drug Programs in Canada, 2012. 
Canadian Institute for Health Information. 2014. https://secure.cihi.ca/
estore/productFamily.htm?locale=en&pf=PFC2594
 24 “Drug-related hospitalizations in a tertiary care internal medicine service 
of a Canadian hospital: A prospective study” Pharmacotherapy. 2006. 
http://www.ncbi.nlm.nih.gov/pubmed/17064202
A key reason for this is that databases concerning 
drug prescribing, use, and outcomes are fragmented 
and uncoordinated, as they are held independently 
by governments, private insurance companies, and 
pharmacy retailers.
The multiplicity of drug plans in Canada can also create 
a burden on prescribing doctors and inhibit safe and 
appropriate prescribing practices. This is because the 
lists of drugs covered by private and public drug plans 
are not coordinated. Many private drug plans cover all 
medicines for any given medical condition, despite the 
lack of evidence showing that widespread use of each 
medicine would be safe and cost-effective.
Despite repeated recommendations that one be 
established, Canada has no national strategy to make 
safe and appropriate prescription drug use part of 
Canadian health care culture. Canada needs such a 
strategy to ensure that patients, professionals, and the 
public have access to the best unbiased information on 
the safe use of medicines.22 
Without a strategy to ensure safe use of medicines, 
Canadians are left vulnerable. An estimated 1 in 3 elderly 
Canadians receives prescriptions for drugs known to 
pose health risks for older patients.23 And an estimated 
1 in 6 hospitalizations in Canada could be prevented if 
prescription drugs were used more appropriately.24
Pharmaceutical coverage needs to be based on the 
best available evidence and integrated into the health 
care system in ways that increase the appropriateness 
of prescribing. By applying a single evidence-based 
formulary — the list of medicines that would be covered for 
all Canadians — Pharmacare would reduce disparities and 
confusion created when different patients are covered
Fewer than 1 in 3 doctors in Canada use 
electronic prescribing tools to help identify 
problems with drug doses or interactions.
Safety
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for different medicines. A single, universal formulary 
would also better guide prescribing than professional 
education alone and would likely improve the quality and 
safety of care received by patients.25
As a universal and publicly managed system, Pharmacare 
would logically integrate with the management of medical 
and hospital care in Canada. This integration would create 
more opportunities for health care professionals and 
health system managers to encourage appropriate use 
of medicines. This approach would be far superior to our 
current system, which involves private insurers that are 
not responsible for other aspects of Canadian health care.
Pharmacare could also foster the routine use of electronic 
prescribing systems and the secure and systematic capture 
of data concerning drug use and outcomes. When linked 
with available health information systems in Canada, this 
could be used for ongoing monitoring and surveillance of 
prescribing practices and drug safety. 
By consistently using evidence and information systems 
to guide drug coverage and prescribing for all Canadians, 
a Pharmacare program could realistically reduce by 50% 
the existing problems of medicine underuse, overuse, and 
misuse. This would dramatically improve patient health 
while reducing costs of medical and hospital care by up to 
$5 billion per year.26  
25 “Sharing resources to create a district drug formulary: A countywide 
controlled trial.” British Journal of General Practice. 1996. http://www.
ncbi.nlm.nih.gov/pubmed/8762741. “Do prescribing formularies help 
GPs prescribe from a narrower range of drugs? A controlled trial of the 
introduction of prescribing formularies for NSAIDs.” British Journal of 
General Practice. 1997. http://www.ncbi.nlm.nih.gov/pubmed/9463982
26 Authors’ calculations based on: “Drug-related hospitalizations in a tertiary 
care internal medicine service of a Canadian hospital: A prospective study.” 
Pharmacotherapy. 2006. http://www.ncbi.nlm.nih.gov/pubmed/17064202 
“Potentially inappropriate medication use and healthcare expenditures in 
the US community-dwelling elderly.” Medical Care. 2007. http://www.ncbi.
nlm.nih.gov/pubmed/17446834 
By helping to reduce problems of medicine 
underuse, overuse, and misuse, Pharmacare 
would dramatically improve patient health 
while saving the health care system up to  
$5 billion per year.
Safety
Recommendation 3: Establish a publicly 
accountable body to manage Pharmacare, one 
that integrates the best available data and 
evidence into decisions concerning drug coverage, 
drug prescribing, and patient follow-up.
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Streamlined and Strengthened Systems to Achieve Better Health 
Outcomes for Every Dollar Spent 
Principle: The cost of medicines 
should be managed to achieve 
maximum value for money 
from the perspective of for 
Canadian society.
A system to provide equitable access to medicines must 
be designed to be efficient and sustainable. This requires 
attention to administrative costs, drug prices, and 
treatments selected to meet health needs. It also requires 
attention to the fact that money spent on pharmaceuticals 
cannot be spent on other things — including other 
investments in health and health care. Canada’s current 
patchwork drug coverage system does poorly in all of 
these respects.
In terms of administrative costs, every private and public 
drug plan operating in every province must spend money 
on beneficiary enrolment, revenue collection, coverage 
decision-making, price negotiations, claims administration, 
and, for private companies, paying shareholders. Many 
of these costs are unnecessarily duplicative, diverting 
resources away from the task of purchasing health care 
for Canadians. 
In terms of drug prices, Canada’s multi-payer system is 
among the most expensive systems in the world, because 
it diminishes our purchasing power. The prices of generic 
drugs in Canada are nearly double (79% higher than) the 
median of prices found in other OECD countries and more 
than four times (445%) higher than the best available prices 
27 Generic Drugs in Canada, 2013. Patented Medicine Prices Review Board. 
2014. http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1122
28 “Comparison of Canadian prices to foreign prices,” in Annual Report 2013. 
Patented Medicine Prices Review Board. 2014. http://www.pmprb-cepmb.
gc.ca/view.asp?ccid=938#1765
in the OECD.27 Similarly, the prices of brand-name drugs in 
Canada are 30% higher than in comparable countries like 
the United Kingdom.28 
Comparable health care systems around the world 
achieve lower prices by using the purchasing power of 
a single payer for pharmaceuticals. Manufacturers who 
price competitively get the reward of their drugs being 
covered for 100% of the population. The savings can be 
remarkable.
Take the blockbuster drug Lipitor, for example. A year’s 
supply of the brand-name drug in Canada costs at least 
$811; in New Zealand, where a public authority negotiates 
prices on behalf of the entire country, a year’s supply of the 
brand costs just $15. Even the generic version of Lipitor 
costs at least $140 in Canada, more than nine times more 
expensive than in New Zealand.
Canada’s provincial governments wield some 
purchasing power when negotiating confidential 
price rebates for prescription drugs subsidized under 
existing public drug plans.29
But these negotiations only apply to drugs used by the 
minority of Canadians who are beneficiaries of public 
drug plans. Uninsured patients and employers who 
insure their workers through private drug plans still face 
unnecessarily high prices.
29 “The pan-Canadian Pharmaceutical Alliance.” Council of the Federation. 
2015  http://www.pmprovincesterritoires.ca/en/initiatives/358-pan-
canadian-pricing-alliance 
“Someone at the end of the day has to pay 
for [medicines], and currently employers 
and unions are bearing that cost. But I don’t 
know how long it can be sustained.”
— Arthur Fabbro Jr. (Magna International)
Value for Money
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In terms of treatments selected to meet health needs, 
Canada’s system does poorly because it isolates 
pharmaceutical management from the management 
of medical care. It is estimated, for example, that 
approximately $5 billion spent by employers on private 
drug benefits is wasted because private drug plans are 
not well positioned to manage prescribing and dispensing 
decisions of Canadian health professionals.30  
In terms of the opportunity cost of money spent on 
pharmaceuticals, Canada’s inefficient system of private 
and public plans makes it easier for managers to pass cost 
increases on to employers, patients, and taxpayers than it 
is for them to manage costs from a system perspective.
Countries comparable to Canada, but with universal 
pharmaceutical coverage integrated into their health care 
systems, use various techniques to encourage clinically 
appropriate, cost-conscious prescribing and product 
selection decisions. These include, for example, evidence-
based formularies and prescribing protocols as well as 
appropriate financial incentives targeting prescribers — not 
patients — to encourage them to consider the full benefits 
and costs of prescribing decisions.31 
As a single-payer drug plan, Pharmacare would have 
the maximum purchasing power — and give maximum 
rewards for manufacturers providing competitively priced 
products. Having a transparent, pre-defined budget is set 
with due consideration of health system priorities and 
resources would ensure program sustainability and health 
system efficiency. 
A publicly accountable body — led with representation 
from the public, prescribers, and governments — would 
establish the national formulary of medicines selected for 
coverage. It would do so in a fair and transparent fashion 
and on the basis of the best available evidence. 
Additionally, as a coordinated system for securing 
medicines in Canada, Pharmacare would be able to use 
best practices in procurement to ensure a safe and secure 
supply of needed medicines.32  
Pharmacare would use the combined purchasing power 
of all provinces and the federal government to ensure 
that Canadians receive the best possible drug prices 
and thereby coverage of the widest possible range of 
treatments at the lowest cost. 
The administrative costs of the single-payer Pharmacare 
system would be $1 billion to $2 billion less than the 
cost of a mixed, private-public system of drug coverage.33 
Private firms could nevertheless provide efficient 
claims administration for the Pharmacare plan and offer 
supplementary insurance for those who would value it.
Independent studies confirm this, estimating that 
Pharmacare would save Canadians between $4 billion 
and $11 billion per year under reasonable assumptions.34 
Thus, when it comes to a prescription drug plan for 
Canada, the best system for patients and population 
health just happens to also be the most economical.
A universal prescription drug plan would mean reduced 
revenues for some businesses that are currently selling 
medicines in Canada at prices higher than are charged in 
comparable countries. However, it would be a significant 
gain for the Canadian economy. Our universal public 
health care systems already provide Canadian employers 
with a competitive advantage of approximately $4/hour.35 
Since pharmaceuticals are the second largest component 
of health care spending in Canada, the cost control 
enabled by a universal, public Pharmacare program would 
add considerably to this advantage.
30 2014 Drug Trend Report. Express Scripts Canada. 2015. 
http://www.express-scripts.ca/research/drug-trend-reports
31 Rethinking Pharmacare in Canada. C.D. Howe Institute. 2013. 
https://www.cdhowe.org/rethinking-pharmacare-in-canada/22009
32 “Canadian Blood Services as a model for national pharmacare.” 
National Post. 2015. http://news.nationalpost.com/full-comment/graham-
sher-canadian-blood-services-as-a-model-for-national-pharmacare. 
International best practices for negotiating ‘reimbursement contracts’ 
with pharmaceutical companies.” Health Affairs. 2012. http://content.
healthaffairs.org/content/32/4/771.abstract 
33 Administrative Costs of Health Insurance Schemes: Exploring the Reasons 
for their Variability. World Health Organization. 2010. http://www.who.int/
health_financing/documents/cov-dp_e_10_08-admin_cost_hi/en/
34 A Roadmap to a Rational Pharmacare Policy in Canada. 2014. Canadian 
Federation of Nurses Unions. https://nursesunions.ca/sites/default/files/
pharmacare_report.pdf. “Estimated cost of universal public coverage of 
prescription drugs in Canada.” Canadian Medical Association Journal. 2015. 
http://www.cmaj.ca/content/early/2015/03/16/cmaj.141564   
 35 A Call for Action: II. Canadian Automotive Partnership Council. 2013. 
http://capcinfo.ca/en/mcwgreport.html
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36 Rethinking Pharmacare in Canada. C.D. Howe Institute. 2013. https://
www.cdhowe.org/rethinking-pharmacare-in-canada/22009
Figure 2: Pharmaceutical 
spending versus 
pharmaceutical research and 
development, Canada and 
official comparator countries 
with universal coverage of 
prescription drugs.
Canadian dollars per capita, 
2012 or closest year.
Value for Money
Recommendation 4: Establish Pharmacare as a 
single-payer system with a publicly accountable 
management agency to secure the best health 
outcomes for Canadians from a transparent 
drug budget.
Finally, it is important to note that achieving financial 
savings through Pharmacare is not a deterrent to other 
key policy goals, including attracting investment in 
pharmaceutical research and development. Canada has the 
highest drug prices and highest levels of total spending 
on pharmaceuticals among comparable countries with 
universal health care systems. Despite this, we also have 
the lowest level of drug coverage, the lowest level of 
medicine access, and the lowest level of pharmaceutical 
research and development (see Figure 2).
The United Kingdom, for example, has better access to 
medicines than Canada does, lower burdens on patients, 
more frequent use of electronic prescribing assistance 
tools, about 45% lower total cost of pharmaceuticals, 
and five times as much pharmaceutical research and 
development on a per capita basis.36 
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The Importance of a Program Budget
To ensure that a drug plan remains financially 
viable, it is important that it be operated at national 
and provincial levels with a transparently defined, 
pre-determined annual budget. 
A program budget will ensure that Pharmacare is 
not perceived as a blank cheque for manufacturers, 
prescribers, and patients, but as a rational system 
maximizing health benefits for every dollar spent on 
medicines and on other investments in Canadians’ health 
and health care. 
Several countries — and virtually every hospital in 
Canada — use prescription budget targets to give health 
care providers and managers an incentive to consider 
the cost of prescribing decisions. Setting budgets for 
pharmaceutical spending in ways that are tied to the 
broader provision of care enables greater clinical 
engagement in pharmaceutical expenditure management. 
When applied judiciously, this approach can be effective 
at reducing overall prescribing and increasing the use of 
generic medicines without impeding patient access to cost-
effective treatments.
At a system level, a budget makes trade-offs between 
pharmaceutical and non-pharmaceutical forms of health 
care for Canadians clear and negotiable at a population 
level. It also gives program managers transparent 
authority to require pharmaceutical manufacturers to 
price their medicine at levels that reflect comparative 
value for money in the Canadian health systems context. 
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Now is the Time to Act
If Canada continues to leave prescription drugs outside its universal public health 
care system, we will continue to see negative impacts on patient health, our 
healthcare system, and the economy as a whole. There is another option.
Pharmacare is achievable and financially sustainable. 
Every comparable universal health care system in the 
world proves that this is the case, because they all provide 
better access to medicines for less than Canada now pays.
Given the recommendations for Pharmacare from 
multiple national commissions in the past, and with the 
mounting evidence and growing calls from a broad range 
of stakeholders and public interest groups, delaying 
implementation is no longer defensible.
Provinces can start right away by building on the 
successes to date with the Pan-Canadian Pharmaceutical 
Alliance, which jointly negotiates prices of patented drugs 
and works to set limits on generic prices. They could 
identify priority stages of Pharmacare development based 
on the priorities of the public health system — for example, 
increased access to and appropriate use of the medicines 
that would generate the greatest benefit to provincial 
health care systems.
A newly elected federal government should commit 
to supporting the nation-wide implementation of a 
comprehensive public Pharmacare system within the 
timeframe of a four-year mandate. This would allow the 
vision and objectives to be articulated at the outset, while 
allowing for careful implementation of this important, 
long-term program. 
Building on Medicare
The recommendations outlined in this report are 
consistent with recommendations of past national 
commissions in Canada. 
They are also consistent with the core principles of 
Canadian Medicare. And, although the Canadian health 
care system can and should perform better, Canadians 
still strongly support the core principles of Medicare 
for sound moral and economic reasons. 
Applied to Pharmacare, these principles would be as 
follows: 
• Universality: No resident is denied coverage because 
of age, income, or any other factor unrelated to his 
or her medical need for covered medicines.
• Accessibility: All residents are able to access covered 
medicines without financial barriers.
• Comprehensiveness: The program covers as many 
medicines as can be afforded and justified by 
available evidence concerning health and economic 
impacts of coverage.
• Public administration: The organization responsible 
for managing the national formulary and related 
pricing and supply contracts is a publicly accountable 
not-for-profit body.
• Portability: The formulary of covered drugs is 
national in scope and provisions are made to ensure 
continuous coverage for residents who move within 
Canada.
Pharmacare would simply add a principle related to 
appropriate use of medicines, which is central to the 
goals and objectives of encouraging access to medically 
necessary prescription drugs:
• Appropriateness: Safety and appropriate medicine 
use must be encouraged and monitored. 
Conclusion
Recommendation 5: Fully implement 
Pharmacare — a public drug plan that is 
universal, comprehensive, evidence-based, and 
sustainable — by 2020. 
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Responsibilities of Governments
Pharmacare would build on public insurance programs run 
by provinces, with provinces and territories continuing to 
finance purchases made in their jurisdictions. 
However, as with Medicare, to ensure participation of 
and consistency between all provinces and territories, 
the federal government should fund a portion of the 
budget for program and operational expenses. Because 
the federal government pays for 25% of Medicare costs, 
including 25% of the cost of drugs used in hospitals, the 
federal share of Pharmacare costs should be set at 25% of 
the program budget.
The federal and provincial governments currently make 
substantial investments in price regulation, health 
technology assessment, and the management of existing 
drug plans. These investments should be coordinated and 
the savings redeployed to manage Pharmacare on a co-
operative, pan-Canadian basis. 
A national committee with representation from the public, 
patients, prescribers, and governments across Canada 
would establish the national formulary of medicines 
selected for coverage on the basis of clinical evidence and 
value for money. This too would build upon and enhance 
processes established in Canada, such as the Common 
Drug Review, the Pan-Canadian Oncology Drug Review, 
and the Pan-Canadian Pharmaceutical Alliance.
Although the program would be a publicly managed, 
single-payer system for covered medicines, private firms 
could provide claims administration or offer supplementary 
insurance for medicines not covered. 
...the federal share of Pharmacare 
costs should be set at 25% of the 
program budget.
Conclusion




Pharmacare will save Canadians money, but it should also 
be designed and budgeted to succeed. This might mean 
an incremental start to program implementation, but it 
must also involve a quick progression to a comprehensive 
program that is sufficiently well-resourced and 
comprehensive to ensure that no Canadian is left behind.
If governments began with a fixed budget and reinvested 
savings from price negotiations and generic substitutions, 
it would be possible to design a program that is cost-
neutral to the public sector — and a significant net savings 
to the private sector. 
However, since Pharmacare will save the private sector up 
to $10 billion, governments should be able to repurpose 
some of those savings to ensure program success. The 
federal government could raise its share of program costs 
through a variety of mechanisms — corporate taxes, income 
taxes, GST, and/or premiums — with a goal of generating 
25% of the total program costs. These should be new funds 
for the program and not funds taken from the existing 
transfers for hospital and medical care. 
A 25% contribution from the federal government 
would enable the implementation of Pharmacare at no 
greater cost to provincial governments than the current 
patchwork of public drug plans costs them. The net 
savings to taxpayers and businesses in Canada would be 
significant — including approximately $3 billion in savings 
to local, provincial, territorial, and federal governments 
that currently finance private drug coverage for public 
sector employees.
The administrative costs of Pharmacare will be lower than 
the current system of financing in Canada. This is partly 
because federal and provincial governments currently 
make substantial investments in price regulation, health 
technology assessment, and the management of existing 
drug plans. These investments would be coordinated 
under Pharmacare and the savings redeployed to run the 
system on a co-operative, pan-Canadian basis.  
Medicare made better
Although the proposed reforms will not go unopposed by 
interests that benefit from the status quo, both evidence 
and international experiences with similar policies clearly 
indicate that these reforms are an economically viable 
way to significantly improve Canadian Medicare.
For patients, Pharmacare designed to be consistent with 
these goals, principles, and recommendations above will 
be a natural extension of their cherished Medicare system. 
For Canadian society, Pharmacare will improve patient 
health, reduce demands elsewhere in the health care 
system, and produce substantial net savings for Canadian 
patients, businesses, and taxpayers. 
Conclusion
Conclusion: Public “Pharmacare” — working in 
conjunction with our “Medicare” system — is the 
best way to give all Canadians equitable access 
to necessary medicines at a fair and affordable 
cost to patients and society as a whole.

